Prime Medicine, Inc.
PRME
$1.27
-$0.07-5.22%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -13.39% | 35.60% | -3.57% | -30.53% | -16.15% |
Total Depreciation and Amortization | 29.28% | 37.69% | 26.05% | 37.57% | 25.00% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 31.18% | 30.61% | 0.82% | 116.30% | 26.85% |
Change in Net Operating Assets | 74.58% | 238.13% | 611.80% | 14.98% | -249.48% |
Cash from Operations | 27.84% | 137.03% | 33.84% | -11.44% | -62.91% |
Capital Expenditure | -4.22% | 2.66% | 56.10% | 3.74% | -16.26% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -30.58% | 16.04% | 248.07% | -70.52% | -225.41% |
Cash from Investing | -28.92% | 16.88% | 233.29% | -75.26% | -192.40% |
Total Debt Issued | 0.00% | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -- | -99.48% | 12,011.01% | -- | 222,439.71% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -96.19% | -99.48% | 12,011.01% | -53.33% | 231,263.24% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -272.28% | 2,804.36% | 182.15% | -199.28% | 197.10% |